Skip to main content
. 2024 Oct 29;25(21):11628. doi: 10.3390/ijms252111628

Figure 6.

Figure 6

Mechanism of action of antibodies targeting IL-6R. (A) Uninhibited IL-6R is activated by its ligand, IL-6, leading to the dimerization of gp-130 and activation of a signaling cascade that activates the pro-inflammatory response. (B) Tocilizumab disrupts the interaction between IL-6R and its ligand (red ✕), preventing gp-130 dimerization and inhibiting the signaling cascade that triggers pro-inflammatory responses (red ✕). The figure was created with BioRender.com.